[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112019008431A2 - aplicação de (s)-norcetamina e sal da mesma como fármaco - Google Patents

aplicação de (s)-norcetamina e sal da mesma como fármaco

Info

Publication number
BR112019008431A2
BR112019008431A2 BR112019008431A BR112019008431A BR112019008431A2 BR 112019008431 A2 BR112019008431 A2 BR 112019008431A2 BR 112019008431 A BR112019008431 A BR 112019008431A BR 112019008431 A BR112019008431 A BR 112019008431A BR 112019008431 A2 BR112019008431 A2 BR 112019008431A2
Authority
BR
Brazil
Prior art keywords
drug
depression
norcetamine
prevention
treatment
Prior art date
Application number
BR112019008431A
Other languages
English (en)
Inventor
Hashimoto Kenji
Original Assignee
Univ Chiba Nat Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chiba Nat Univ Corp filed Critical Univ Chiba Nat Univ Corp
Publication of BR112019008431A2 publication Critical patent/BR112019008431A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

a presente invenção refere-se a: um fármaco para a prevenção e/ou o tratamento de um sintoma de depressão, o fármaco compreendendo (s)-norcetamina ou um sal farmacologicamente aceitável da mesma; uma composição farmacêutica para a prevenção e/ou o tratamento de um sintoma de depressão, a composição contendo (s)-norcetamina ou um sal farmacologicamente aceitável da mesma em uma quantidade eficaz para aliviar sintomas de depressão, e substancialmente não contendo (r)-norcetamina; um método para a prevenção e/ou o tratamento de sintomas de depressão, o método incluindo a administração do fármaco ou da composição; e uso de (s)-norcetamina na produção de um fármaco para a prevenção e/ou o tratamento de sintomas de depressão ou uma composição para a prevenção e/ou o tratamento de sintomas de depressão.
BR112019008431A 2016-10-27 2017-10-27 aplicação de (s)-norcetamina e sal da mesma como fármaco BR112019008431A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016210749 2016-10-27
PCT/JP2017/038826 WO2018079693A1 (ja) 2016-10-27 2017-10-27 （ｓ）－ノルケタミンおよびその塩の医薬品としての応用

Publications (1)

Publication Number Publication Date
BR112019008431A2 true BR112019008431A2 (pt) 2019-07-09

Family

ID=62023567

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019008431A BR112019008431A2 (pt) 2016-10-27 2017-10-27 aplicação de (s)-norcetamina e sal da mesma como fármaco

Country Status (9)

Country Link
US (1) US20190240184A1 (pt)
EP (1) EP3533444A4 (pt)
JP (3) JPWO2018079693A1 (pt)
CN (1) CN110167541A (pt)
AU (1) AU2017351437B2 (pt)
BR (1) BR112019008431A2 (pt)
CA (1) CA3041275A1 (pt)
IL (2) IL315066A (pt)
WO (1) WO2018079693A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020529445A (ja) 2017-07-31 2020-10-08 スモール ファーマ リミテッド ヒドロキシノルケタミンの結晶形態
GB201808150D0 (en) * 2018-05-18 2018-07-11 Small Pharma Ltd Therapeutic compounds
JP7167168B2 (ja) 2018-01-10 2022-11-08 エックスダブリューファルマ リミテッド ケタミンのプロドラッグ、組成物及びそれらの使用
CN108863873A (zh) * 2018-06-26 2018-11-23 台州学院 一种硫烯丙基碳酸酯类化合物及其制备方法
BR112020023882A2 (pt) 2018-06-27 2021-02-09 Clexio Biosciences Ltd. método para tratar transtorno depressivo maior
AU2019352028A1 (en) 2018-10-05 2021-03-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
CN110538169B (zh) * 2019-05-24 2020-08-25 北京大学深圳研究生院 一种长效化合物在制备药物中的应用
CN110559282A (zh) * 2019-08-02 2019-12-13 华中科技大学同济医学院附属同济医院 去甲氯胺酮在制备抗抑郁的药物中的应用
AU2020410549A1 (en) * 2019-12-20 2022-04-14 Alar Pharmaceuticals Inc. Long-acting injectable formulations of ketamine pamoate salts
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regimen with escitamine for the treatment of clinical depression
WO2022041172A1 (zh) * 2020-08-31 2022-03-03 深圳瑞健生物科技有限公司 一种长效低成瘾性化合物在制备药物中的应用
CN112521295B (zh) * 2020-08-31 2021-10-08 深圳瑞健生物科技有限公司 一种长效低成瘾性化合物及其制备方法
KR20230024383A (ko) * 2020-08-31 2023-02-20 선전 루이지엔 바이오테크놀로지 컴퍼니 리미티드 장기 작용성 및 저중독성 화합물 및 그의 제조 방법
WO2022041175A1 (zh) * 2020-08-31 2022-03-03 深圳瑞健生物科技有限公司 一种长效低成瘾性hnk衍生物在制备药物中的应用
US11690811B2 (en) 2021-08-13 2023-07-04 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives
EP4289815A1 (en) * 2022-06-10 2023-12-13 Pcas Crystalline forms of norketamine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
CA2506615A1 (en) * 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
CA2851619C (en) * 2011-10-14 2021-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of hydroxynorketamine, dehydronorketamine and other ketamine metabolites in the treatment of depression and neuropathic pain
KR20140136982A (ko) * 2012-03-12 2014-12-01 얀센 파마슈티카 엔.브이. 치료-불응성 또는 치료-저항성 우울증 치료용 에스케타민
PT3043785T (pt) 2013-09-13 2021-11-05 Univ Chiba Nat Univ Corp Aplicação de r-cetamina e seu sal como medicamentos
WO2015051259A1 (en) * 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
EP3725307A1 (en) * 2014-09-15 2020-10-21 Janssen Pharmaceutica NV Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
US10252982B2 (en) * 2014-11-04 2019-04-09 Amorsa Therapeutics, Inc. Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
JP6304121B2 (ja) 2015-05-13 2018-04-04 信越化学工業株式会社 紫外線吸収性有機ケイ素化合物、塗料、及び積層体

Also Published As

Publication number Publication date
AU2017351437B2 (en) 2022-01-27
AU2017351437A1 (en) 2019-06-06
EP3533444A1 (en) 2019-09-04
EP3533444A4 (en) 2020-05-20
CN110167541A (zh) 2019-08-23
JP2022081648A (ja) 2022-05-31
JPWO2018079693A1 (ja) 2019-10-31
IL315066A (en) 2024-10-01
WO2018079693A9 (ja) 2018-07-26
CA3041275A1 (en) 2018-05-03
JP2024038066A (ja) 2024-03-19
US20190240184A1 (en) 2019-08-08
WO2018079693A1 (ja) 2018-05-03
IL266133A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112015019720B8 (pt) Inibidores de (benzil-ciano-metil)-amidas de ácido 2-azabiciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c e composição farmacêutica
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112017023904A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015027682A2 (pt) Uso de sobetirome no tratamento de doenças ou condições associadas com a desmielinização ou mielinização insuficiente
BR112019003932A2 (pt) composto, composição farmacêutica, combinação, método de tratamento de uma doença ou desordem e uso do composto
BR112012030029A2 (pt) beta-lactamases modificadas e métodos e usos relacionados a elas
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112017015123A2 (pt) derivados de indol como inibidores da replicação viral do dengue
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]